Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S
Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, 4306A Walker Building, Auburn University, Auburn, AL, 36849, USA.
Harrison School of Pharmacy, Walker Building, Auburn University, Auburn, AL, 36849, USA.
Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720. Epub 2020 Dec 24.
High and ever-increasing costs of Multiple Sclerosis (MS) disease-modifying therapies (DMTs) have impaired patient access to DMTs in the US. Patients' willingness-to-pay (WTPs) for DMTs were recently examined, but their influencers were not determined. Thus, the objective of this study was to examine factors influencing patients' WTPs for DMTs for multiple sclerosis (MS).
Data were obtained from a previous survey of 1,200 US patients with MS on their preferences and WTPs for DMTs. Patients' characteristics (i.e., age, gender, race, marital status, education, employment status, comorbidity, health status, and health insurance) and their MS experiences (i.e., number of years with MS, MS type, number of relapses, fatigue, mood-change, MS symptom, and DMTs experience) were investigated as influencing factors. Patient's WTP for a DMT was obtained from a direct question in the survey. A two-part model was estimated using logistic regression and generalized linear regression.
Responses from 480 patients were analyzed. Their average age was 53 years old. Most of them were female (79%), white (97%), and married (71%). Approximately 61% of them had a four-year college degree or lower, 54% were either unemployed, retired, or students, 59% were enrolled in private insurance, 81% had at least one comorbid condition, and 73% considered themselves having good or better health status. Approximately 44% had at least one relapse in two years, 89% experienced fatigue, 37% experienced mood-change, and on average had MS for more than 13 years. The majority of them had relapsing-remitting MS (66%), considered themselves to have some levels of disability for MS (78%), and had used or were currently using DMTs (97%). The average WTP for a DMT was $579 per month. Patients with professional degrees, or with one or more comorbid conditions were more likely willing to pay for a DMT. Patients who were white, had a professional degree, or were in fair or better health status were willing to pay a significantly higher amount for a DMT. Patients, who were female, were employed, did not have private insurance, had a higher number of MS experience years, or who experienced mood change were willing to pay significantly less amount for a DMT.
Various patients' characteristics and MS experiences, including gender, race, education, employment, health insurance, comorbidity, health status, DMT experience, and mood change influenced patients' WTPs for a DMT.
在美国,多发性硬化症(MS)疾病修正疗法(DMTs)高昂且持续上涨的成本影响了患者获得DMTs的机会。最近对患者支付DMTs的意愿(WTPs)进行了研究,但尚未确定影响因素。因此,本研究的目的是探讨影响多发性硬化症(MS)患者支付DMTs意愿的因素。
数据来自之前对1200名美国MS患者进行的关于他们对DMTs的偏好和支付意愿的调查。调查了患者的特征(即年龄、性别、种族、婚姻状况、教育程度、就业状况、合并症、健康状况和健康保险)以及他们的MS经历(即患MS的年数、MS类型、复发次数、疲劳、情绪变化、MS症状和DMTs使用经历)作为影响因素。患者对DMT的支付意愿是通过调查中的一个直接问题获得的。使用逻辑回归和广义线性回归估计两部分模型。
分析了480名患者的回复。他们的平均年龄为53岁。大多数为女性(79%)、白人(97%)且已婚(71%)。约61%的患者拥有四年制大学学位或更低学历,54%为失业、退休或学生,59%参加了私人保险,81%至少有一种合并症,73%认为自己健康状况良好或更好。约44%的患者在两年内至少有一次复发,89%经历过疲劳,37%经历过情绪变化,平均患MS超过13年。他们中的大多数患有复发缓解型MS(66%),认为自己因MS有一定程度的残疾(78%),并且已经使用或正在使用DMTs(97%)。DMT的平均支付意愿为每月579美元。拥有专业学位或有一种或多种合并症的患者更愿意为DMT付费。白人、拥有专业学位或健康状况良好或更好的患者愿意为DMT支付显著更高的金额。女性、就业、没有私人保险、MS经历年数较多或经历过情绪变化的患者愿意为DMT支付的金额显著较少。
患者的各种特征和MS经历,包括性别、种族、教育程度、就业、健康保险、合并症、健康状况、DMT使用经历和情绪变化,都会影响患者对DMT的支付意愿。